Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome + 5-fluorouracil/leucovorin + PD-L1 inhibitor and radiotherapy as first-line therapy in advanced biliary tract cancer
ChiCTR2600118896Phase 4Completed
- Sponsor
- Xiangyang Central Hospital
- Start
- Feb 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan liposome, fluorouracil and folinic acid in gallbladder cancer and cholangiocarcinoma (CCA), sponsored by Xiangyang Central Hospital. Primary endpoint: Progression-free survival. Started Feb 2026; status: completed.
02
Drugs
irinotecan liposomefluorouracilfolinic acid
03
Conditions
gallbladder cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2600118896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118896.